129 related articles for article (PubMed ID: 10048977)
1. Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance.
Lage H; Christmann M; Kern MA; Dietel M; Pick M; Kaina B; Schadendorf D
Int J Cancer; 1999 Mar; 80(5):744-50. PubMed ID: 10048977
[TBL] [Abstract][Full Text] [Related]
2. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy.
Ma S; Egyházi S; Ringborg U; Hansson J
Oncol Rep; 2002; 9(5):1015-9. PubMed ID: 12168066
[TBL] [Abstract][Full Text] [Related]
4. Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants.
Brieger A; Trojan J; Raedle J; Plotz G; Zeuzem S
Gut; 2002 Nov; 51(5):677-84. PubMed ID: 12377806
[TBL] [Abstract][Full Text] [Related]
5. Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer.
Kitajima Y; Miyazaki K; Matsukura S; Tanaka M; Sekiguchi M
Gastric Cancer; 2003; 6(2):86-95. PubMed ID: 12861399
[TBL] [Abstract][Full Text] [Related]
6. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.
Geisler JP; Goodheart MJ; Sood AK; Holmes RJ; Hatterman-Zogg MA; Buller RE
Cancer; 2003 Nov; 98(10):2199-206. PubMed ID: 14601090
[TBL] [Abstract][Full Text] [Related]
7. Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study.
Stefansson I; Akslen LA; MacDonald N; Ryan A; Das S; Jacobs IJ; Salvesen HB
Clin Cancer Res; 2002 Jan; 8(1):138-43. PubMed ID: 11801550
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
Christmann M; Pick M; Lage H; Schadendorf D; Kaina B
Int J Cancer; 2001 Apr; 92(1):123-9. PubMed ID: 11279615
[TBL] [Abstract][Full Text] [Related]
10. Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma.
Kohya N; Miyazaki K; Matsukura S; Yakushiji H; Kitajima Y; Kitahara K; Fukuhara M; Nakabeppu Y; Sekiguchi M
Ann Surg Oncol; 2002 May; 9(4):371-9. PubMed ID: 11986189
[TBL] [Abstract][Full Text] [Related]
11. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
12. [Effect of eukaryotic expression plasmid DNA methyltransferase gene on methylation status and transcription level of DNA mismatch repair genes in human colon cancer cell line].
Lu R; Fang JY; Zhu HY; Chen YX; Cheng ZH; Li EL
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(12):1014-7. PubMed ID: 15312538
[TBL] [Abstract][Full Text] [Related]
13. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
14. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.
Samimi G; Fink D; Varki NM; Husain A; Hoskins WJ; Alberts DS; Howell SB
Clin Cancer Res; 2000 Apr; 6(4):1415-21. PubMed ID: 10778972
[TBL] [Abstract][Full Text] [Related]
15. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
[TBL] [Abstract][Full Text] [Related]
16. Mutations in mismatch repair genes are involved in the neoplastic transformation of human breast epithelial cells.
Balogh GA; Russo IH; Russo J
Int J Oncol; 2003 Aug; 23(2):411-9. PubMed ID: 12851690
[TBL] [Abstract][Full Text] [Related]
17. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.
de las Alas MM; Aebi S; Fink D; Howell SB; Los G
J Natl Cancer Inst; 1997 Oct; 89(20):1537-41. PubMed ID: 9337351
[TBL] [Abstract][Full Text] [Related]
18. DNA mismatch repair genes hMLH1, hMSH2, and hMSH6 are not inactivated in bronchioloalveolar carcinomas of the lung.
Aubry MC; Halling KC; Myers JL; Tazelaar HD; Yang P; Thibodeau SN
Cancer; 2001 Dec; 92(11):2898-901. PubMed ID: 11753964
[TBL] [Abstract][Full Text] [Related]
19. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
20. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
